PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
150.15%
Net income growth 1.25-1.5x CRK's 114.41%. Bruce Berkowitz would verify whether cost discipline or revenue gains drive the outperformance.
5.84%
D&A growth well above CRK's 10.90%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
11.63%
Lower deferred tax growth vs. CRK's 107.60%, implying fewer future tax liabilities. David Dodd would confirm there’s no short-term tax shock instead.
No Data
No Data available this quarter, please select a different quarter.
98.40%
Slight usage while CRK is negative at -2675.27%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
98.40%
Growth of 98.40% while CRK is zero at 0.00%. Bruce Berkowitz would see a difference in minor WC usage that might affect short-term cash flow if large.
160.04%
Some yoy increase while CRK is negative at -77.60%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
107.95%
Operating cash flow growth above 1.5x CRK's 6.88%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
-10.91%
Negative yoy CapEx while CRK is 35.72%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
-100.00%
Negative yoy acquisition while CRK stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
-100.00%
Negative yoy purchasing while CRK stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
-100.00%
We reduce yoy sales while CRK is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
208.20%
Growth of 208.20% while CRK is zero at 0.00%. Bruce Berkowitz sees a moderate difference requiring justification by ROI in these smaller invests.
94.82%
Investing outflow well above CRK's 35.72%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
7.38%
Lower share issuance yoy vs. CRK's 205.15%, implying less dilution. David Dodd would confirm the firm still has enough capital for expansions.
No Data
No Data available this quarter, please select a different quarter.